Table 1.

Patient characteristics. CNI—calcineurin inhibitor; LT—liver transplantation; HCC—hepatocellular cancer; mTOR—mTOR Inhibitor; MMF—mycophenolate mofetil; HBIG—hepatitis B immunoglobulin; NA—nucleos(t)ide analog; standard group–life-long combination of HBIG with NA; discontinuation group—NA-based and discontinuation of HBIG.

Patient Characteristic	Standard (NA + HBIG)	Discontinuation (NA + HBIG-)	p
Total patients (%)			0.74
Male	9 (47.4)	9 (52.9)
Female	10 (52.6)	8 (47.1)
Median age at LT (min–max)	45 (32–59)	42 (20–62)	0.95
HBV/HDV infection (%)	19 (100)	17 (100)
HBsAG+/HBV-DNA+ at LT	17 (89.5)	15 (88.2)	0.91
HBV reinfection after LT	4 (21.1)	5 (29.4)	0.56
HDV reinfection after LT	0 (0)	1 (5.9)	0.11
HCV infection at LT (%)	7 (36.8)	4 (23.5)	0.43
HCV reinfection after LT	3 (42.9)	2 (50.0)
HCC at LT (%)	4 (21.1)	7 (41.2)	0.43
Re-transplantation (%)	2 (10.5)	2 (11.8)	0.26
Rejection	0 (0)	1 (5.9)
Reinfection	0 (0)	1 (5.9)
Surgical complications	2 (10.5)	0 (0)
HBV/HDV prophylaxis after LT (%)			0.11
NA: low genetic barrier	10 (52.6)	9 (52.9)
NA: high genetic barrier	7 (36.8)	4 (23.5)
IFN	2 (10.5)	1 (5.9)
HBIg monotherapy	0 (0)	5 (29.4)
Median HBIG titer (U/L) during combination therapy in (min–max)	215.5 (140–845)	199 (102–1000)	0.40
Recent immune suppression (%)
CNI	17 (68.4)	15 (58.8)	0.55
MMF	8 (42.1)	7 (41.2)	0.92
mTOR	0 (0)	1 (5.9)	0.28
others	1 (5.3)	1 (5.9)	0.93
combination
CNI/MMF	7 (36.8)	5 (29.4)
others	1 (5.3)	1 (5.9)
Median follow-up after LT (min–max)	227 (24–381)	204 (7–360)	0.69
Median time of HBIG discontinuation after LT (min–max)	n.a.	72 (0–312)	n.a.
Median time after HBIG discontinuation (min–max)	n.a.	120 (6–360)	n.a.
Deceased (%)	7 (36.8)	3 (17.6)	0.2